SEPNSepterna, Inc.
Price
+144%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, undemanding price, growing in the filings, the market undecided.
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (“GPCR”) oral small molecule drug discovery powered by our proprietary Native Complex Platform®. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
In the company’s own words · 10-K filed Mar 9, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Septerna, Inc. (SEPN) reported revenue of $27M in Q2 2026 (quarter ended Jun 30, 2026), up 22376% from the same quarter a year earlier. That came with net loss of $13M. For the full year FY2025, revenue was $46M (+4175% year on year) and net income −$49M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 25, 2026Effective August 24, 2026, the Company’s Board of Directors appointed Rajiv Patni, M.D., as the Company’s Chief Medical Officer.Regulation FD disclosure · Form 8-K
- Aug 10, 2026Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 11, 2026Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry